RLRL: A New Myopia Control Strategy
Provider: Mivision
Contact: Nikki Byrne, [E] nikki@mivision.com.au, [P] 02 8336 8616
Activity Outline
Professor Mingguang He presents the evidence to support the Eyerising, a home-use device originally intended for amblyopia treatment in China, which is successfully being used to slow myopia progression.
Learning Objectives
- Acquire a comprehensive understanding of the Repeated Low-Level Red-Light (RLRL) Therapy, its underlying principles, and its pivotal role in myopia management, emphasizing its strong efficacy in controlling myopia progression, and the observed phenomenon of axial shortening post-treatment
- Understand the safety standards and guidelines of RLRL Therapy, drawing insights from ANSI light hazard testing, and gain practical guidance for its clinical adoption
- Explore the potential future applications of RLRL Therapy, its efficacy when combined with other treatment modalities, and its role in reducing the prevalence of myopia and associated complications in the community
Max CPD hours awarded: 1.25
Session Information
| Name |
|---|
| RLRL: A New Myopia Control Strategy |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| No |
| Duration of CPD Session/Module |
| 0.75 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 1.25 |